MoonLake Immunotherapeutics/$MLTX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.
Ticker
$MLTX
Sector
Primary listing
Industry
Biotechnology
Headquarters
Zug, Switzerland
Employees
100
ISIN
KY61559X1045
Website
MLTX Metrics
BasicAdvanced
$3.1B
-
-$2.30
1.31
-
Price and volume
Market cap
$3.1B
Beta
1.31
52-week high
$58.26
52-week low
$31.42
Average daily volume
647K
Financial strength
Current ratio
21.111
Quick ratio
20.146
Long term debt to equity
17.976
Total debt to equity
18.323
Interest coverage (TTM)
-9,486.45%
Profitability
EBITDA (TTM)
-169.321
Effective tax rate (TTM)
-0.25%
Management effectiveness
Return on assets (TTM)
-19.85%
Return on equity (TTM)
-30.64%
Valuation
Price to book
7.61
Price to tangible book (TTM)
7.61
Price to free cash flow (TTM)
-21.984
Free cash flow yield (TTM)
-4.55%
Free cash flow per share (TTM)
-222.35%
Growth
Earnings per share change (TTM)
211.65%
Bulls say / Bears say
Guggenheim Securities reiterated their Buy rating and $80 price target for MoonLake Immunotherapeutics, highlighting confidence in the company's prospects. (Investing.com)
Cowen analysts project that MoonLake's lead drug candidate, sonelokimab, could achieve peak revenues exceeding $4 billion, indicating a strong commercial outlook. (Investing.com)
MoonLake secured a $500 million non-dilutive debt facility, extending its cash runway into 2028, providing financial stability for ongoing and future projects. (StockTitan)
MoonLake's stock dropped approximately 25% after reporting ambiguous results for its psoriatic arthritis treatment, where placebo recipients showed better-than-expected improvements. (Proactive Investors)
Director Simon Sturge sold 171,000 shares, reducing his ownership by nearly 50%, which could signal a lack of confidence in the company's near-term prospects. (ETF Daily News)
JPMorgan Chase & Co. reduced its holdings in MoonLake, potentially indicating decreased institutional confidence in the company's future performance. (Defense World)
Data summarised monthly by Lightyear AI. Last updated on 10 Jul 2025.
MLTX News
AllArticlesVideos
Merck held talks to buy biotech MoonLake for over $3 billion, FT reports
Reuters·1 month ago
MoonLake Immunotherapeutics Reports First Quarter 2025 Financial Results and Provides a Business Update
GlobeNewsWire·2 months ago
MoonLake Immunotherapeutics to host a Capital Markets Day on Tuesday, April 29
GlobeNewsWire·3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for MoonLake Immunotherapeutics stock?
MoonLake Immunotherapeutics (MLTX) has a market cap of $3.1B as of July 11, 2025.
What is the P/E ratio for MoonLake Immunotherapeutics stock?
The price to earnings (P/E) ratio for MoonLake Immunotherapeutics (MLTX) stock is 0 as of July 11, 2025.
Does MoonLake Immunotherapeutics stock pay dividends?
No, MoonLake Immunotherapeutics (MLTX) stock does not pay dividends to its shareholders as of July 11, 2025.
When is the next MoonLake Immunotherapeutics dividend payment date?
MoonLake Immunotherapeutics (MLTX) stock does not pay dividends to its shareholders.
What is the beta indicator for MoonLake Immunotherapeutics?
MoonLake Immunotherapeutics (MLTX) has a beta rating of 1.31. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.